Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission

Nanomedicine

Volumn 10, Issue 6, 2015, Pages 899-914

  Sepúlveda Crespo, Daniel ^a   Sánchez Rodríguez, Javier ^a   Serramía, María Jesús ^a   Gómez, Rafael ^b   De La Mata, Francisco Javier ^b   Jiménez, José Luis ^a   Muñoz Fernández, Ma Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

carbosilane dendrimer; HIV 1; maraviroc; microbicide; nanomedicine; synergy; tenofovir; triple combination; vaginal irritation

Indexed keywords

DENDRIMER; G2 S16; G2 S24P; G2 STE16; MARAVIROC; MICROBICIDE; SILANE DERIVATIVE; TENOFOVIR; UNCLASSIFIED DRUG; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CARBOSILANE; CYCLOHEXANE DERIVATIVE; DRUG COMBINATION; PHOSPHONIC ACID DERIVATIVE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BIOCOMPATIBILITY; BIOSAFETY; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEMINAL PLASMA; SEXUAL TRANSMISSION; SEXUALLY TRANSMITTED DISEASE; TOXICITY TESTING; VAGINA EPITHELIUM; VIRUS REPLICATION; VIRUS TRANSMISSION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; COMPUTER PROGRAM; DRUG COMBINATION; DRUG EFFECTS; HIV INFECTIONS; MUCOSA; TRANSMISSION; VAGINA; VIROLOGY;

ADENINE; ANIMALS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; CELL SURVIVAL; CYCLOHEXANES; DENDRIMERS; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; ORGANOPHOSPHONATES; SILANES; SOFTWARE; TRIAZOLES; VAGINA;

EID: 84928164425     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.14.79     Document Type: Article

References (101)

1. Coma Auli N, Mejia-Lancheros C, Berenguera A, Mayans MV, Lasagabaster MA, Pujol-Ribera E. Risk perception of sexually transmitted infections and HIV in Nigerian commercial sex workers living in Barcelona: a study protocol. BMJ Open 3(7), doi: 10.1136/bmjopen-2013-003345 (2013).
2. Koff WC. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Vaccine 30(29), 4310-4315 (2012).
3. Letvin NL. Progress and obstacles in the development of an AIDS vaccine. Nat. Rev. Immunol. 6(12), 930-939 (2006).
4. Pruss-Ustun A, Wolf J, Driscoll T, Degenhardt L, Neira M, Calleja JM. HIV due to female sex work: regional and global estimates. PLoS ONE 8(5), e63476 (2013).
5. Gupta GR. How men's power over women fuels the HIV epidemic. BMJ 324(7331), 183-184 (2002).
6. Murphy EM, Greene ME, Mihailovic A, Olupot-Olupot P. Was the "ABC" approach (abstinence, being faithful, using condoms) responsible for Uganda's decline in HIV? PLoS Med. 3(9), e379 (2006).
7. Randolph ME, Pinkerton SD, Bogart LM, Cecil H, Abramson PR. Sexual pleasure and condom use. Arch. Sex. Behav. 36(6), 844-848 (2007).
8. Underhill K, Montgomery P, Operario D. Sexual abstinence only programmes to prevent HIV infection in high income countries: systematic review. BMJ 335(7613), 248 (2007).
9. Wawer MJ, Makumbi F, Kigozi G et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet 374(9685), 229-237 (2009).
10. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst. Rev. 1, CD003255 (2002).
11. Lackman-Smith C, Osterling C, Luckenbaugh K et al. Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides. Antimicrob. Agents Chemother. 52(5), 1768-1781 (2008).
12. Buckheit RW Jr, Watson KM, Morrow KM, Ham AS. Development of topical microbicides to prevent the sexual transmission of HIV. Antiviral Res. 85(1), 142-158 (2010).
13. Swanson MD, Winter HC, Goldstein IJ, Markovitz DM. A lectin isolated from bananas is a potent inhibitor of HIV replication. J. Biol. Chem. 285(12), 8646-8655 (2010).
14. Moulard M, Lortat-Jacob H, Mondor I et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J. Virol. 74(4), 1948-1960 (2000).
15. Richardson BA, Lavreys L, Martin HL Jr et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex. Transm. Dis. 28(7), 394-400 (2001).
16. Peterson L, Nanda K, Opoku BK et al. SAVVY (C31G) gel for prevention of HIV infection in women: a Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE 2(12), e1312 (2007).
17. Skoler-Karpoff S, Ramjee G, Ahmed K et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372(9654), 1977-1987 (2008).
18. Van Damme L, Govinden R, Mirembe FM et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359(5), 463-472 (2008).
19. Abdool Karim SS, Richardson BA, Ramjee G et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25(7), 957-966 (2011).
20. Dumond JB, Patterson KB, Pecha AL et al. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J. Acquir. Immune Defic. Syndr. 51(5), 546-553 (2009).
21. Emau P, Tian B, O'keefe B R et al. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J. Med. Primatol. 36(4-5), 244-253 (2007).
22. Lederman MM, Veazey RS, Offord R et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 306(5695), 485-487 (2004).
23. Tsai CC, Emau P, Jiang Y et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. Hum. Retroviruses 20(1), 11-18 (2004).
24. Schwartz JL, Kovalevsky G, Lai JJ et al. A randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. Sex. Transm. Dis. 35(4), 414-419 (2008).
25. Singer R, Derby N, Rodriguez A et al. The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J. Virol. 85(11), 5504-5512 (2011).
26. Nel AM, Smythe SC, Habibi S, Kaptur PE, Romano JW. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel. J. Acquir. Immune Defic. Syndr. 55(2), 161-169 (2010).
27. Sokal DC, Karim QA, Sibeko S et al. Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. Antivir. Ther. 18(3), 301-310 (2013).
28. Abdool Karim Q, Abdool Karim SS, Frohlich JA et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329(5996), 1168-1174 (2010).
29. Celum C, Baeten JM. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Curr. Opin. Infect. Dis. 25(1), 51-57 (2012).
30. Peters BS, Conway K. Therapy for HIV: past, present, and future. Adv. Dent. Res. 23(1), 23-27 (2011).
31. Doncel GF, Clark MR. Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers. Antiviral Res. 88(Suppl. 1), S10-S18 (2010).
32. Das Neves J, Amiji MM, Bahia MF, Sarmento B. Nanotechnology-based systems for the treatment and prevention of HIV/AIDS. Adv. Drug Deliv. Rev. 62(4-5), 458-477 (2010).
33. Date AA, Destache CJ. A review of nanotechnological approaches for the prophylaxis of HIV/AIDS. Biomaterials 34(26), 6202-6228 (2013).
34. Parboosing R, Maguire GE, Govender P, Kruger HG. Nanotechnology and the treatment of HIV infection. Viruses 4(4), 488-520 (2012).
35. Mamo T, Moseman EA, Kolishetti N et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond.) 5(2), 269-285 (2010).
36. Du Toit LC, Pillay V, Choonara YE. Nano-microbicides: challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS. Adv. Drug Deliv. Rev. 62(4-5), 532-546 (2010).
37. Chen MY, Millwood IY, Wand H et al. A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis. J. Acquir. Immune Defic. Syndr. 50(4), 375-380 (2009).
38. O'loughlin J, Millwood IY, Mcdonald HM, Price CF, Kaldor JM, Paull JR. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study. Sex. Transm. Dis. 37(2), 100-104 (2010).
39. Price CF, Tyssen D, Sonza S et al. SPL7013 Gel (VivaGel(R)) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS ONE 6(9), e24095 (2011).
40. Moscicki AB, Kaul R, Ma Y et al. Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety. J. Acquir. Immune Defic. Syndr. 59(2), 134-140 (2012).
41. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. Lancet 372(9639), 669-684 (2008).
42. Belec L, Jenabian MA, Charpentier C, Saidi H. Combinatorial prevention of HIV transmission in women: the case for a vaginal microbicide. Future Microbiol. 6(7), 731-737 (2011).
43. Abdool Karim SS, Baxter C. Overview of microbicides for the prevention of human immunodeficiency virus. Best Pract. Res. Clin. Obstet. Gynaecol. 26(4), 427-439 (2012).
44. Chonco L, Pion M, Vacas E et al. Carbosilane dendrimer nanotechnology outlines of the broad HIV blocker profile. J. Control. Release 161(3), 949-958 (2012).
45. Cordoba EV, Arnaiz E, De La Mata FJ et al. Synergistic activity of carbosilane dendrimers in combination with maraviroc against HIV in vitro. AIDS 27(13), 2053-2058 (2013).
46. Galan M, Sanchez-Rodriguez J, Cangiotti M et al. Antiviral properties against HIV of water soluble copper carbosilane dendrimers and their EPR characterization. Curr. Med. Chem. 19(29), 4984-4994 (2012).
47. Garcia-Gallego S, Cangiotti M, Fiorani L et al. Anionic sulfonated and carboxylated PPI dendrimers with the EDA core: synthesis and characterization of selective metal complexing agents. Dalton Trans. 42(16), 5874-5889 (2013).
48. Garcia-Gallego S, Rodriguez JS, Jimenez JL et al. Polyanionic N-donor ligands as chelating agents in transition metal complexes: synthesis, structural characterization and antiviral properties against HIV. Dalton Trans. 41(21), 6488-6499 (2012).
49. Sepulveda-Crespo D, Lorente R, Leal M et al. Synergistic activity profile of carbosilane dendrimer G2-STE16 in combination with other dendrimers and antiretrovirals as topical anti-HIV-1 microbicide. Nanomedicine 10(3), 609-618 (2013).
50. Vacas Cordoba E, Arnaiz E, Relloso M et al. Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission. AIDS 27(8), 1219-1229 (2013).
51. Rasines B, Sanchez-Nieves J, Maiolo M et al. Synthesis, structure and molecular modelling of anionic carbosilane dendrimers. Dalton Trans. 41(41), 12733-12748 (2012).
52. Herrera C, Cranage M, Mcgowan I, Anton P, Shattock RJ. Reverse transcriptase inhibitors as potential colorectal microbicides. Antimicrob. Agents Chemother. 53(5), 1797-1807 (2009).
53. Iser DM, Warner N, Revill PA et al. Coinfection of hepatic cell lines with human immunodeficiency virus and hepatitis B virus leads to an increase in intracellular hepatitis B surface antigen. J. Virol. 84(12), 5860-5867 (2010).
54. Wei X, Decker JM, Liu H et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46(6), 1896-1905 (2002).
55. Garcia-Merino I, De Las Cuevas N, Jimenez JL et al. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology 6, 27 (2009).
56. Garcia-Merino I, De Las Cuevas N, Jimenez JL et al. Pediatric HIV BioBank: a new role of the Spanish HIV BioBank in pediatric HIV research. AIDS Res. Hum. Retroviruses 26(2), 241-244 (2010).
57. Freed EO, Englund G, Martin MA. Role of the basic domain of human immunodeficiency virus type 1 matrix in macrophage infection. J. Virol. 69(6), 3949-3954 (1995).
58. Adachi A, Gendelman HE, Koenig S et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59(2), 284-291 (1986).
59. Collman R, Balliet JW, Gregory SA et al. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J. Virol. 66(12), 7517-7521 (1992).
60. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55 (1984).
61. Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58(3), 621-681 (2006).
62. Belen'kii MS, Schinazi RF. Multiple drug effect analysis with confidence interval. Antiviral Res. 25(1), 1-11 (1994).
63. Lee JJ, Kong M. Confidence intervals of interaction index for assessing multiple drug interaction. Stat. Biopharm. Res. 1(1), 4-17 (2009).
64. Rasheed S, Li Z, Xu D. Human immunodeficiency virus load. Quantitative assessment in semen from seropositive individuals and in spiked seminal plasma. J. Reprod. Med. 40(11), 747-757 (1995).
65. Allen RD, Roberts TK. Role of spermine in the cytotoxic effects of seminal plasma. Am. J. Reprod. Immunol. Microbiol. 13(1), 4-8 (1987).
66. Adams JL, Kashuba AD. Formulation, pharmacokinetics and pharmacodynamics of topical microbicides. Best Pract. Res. Clin. Obstet. Gynaecol. 26(4), 451-462 (2012).
67. Cutler B, Justman J. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect. Dis. 8(11), 685-697 (2008).
68. Costin GE, Raabe HA, Priston R, Evans E, Curren RD. Vaginal irritation models: the current status of available alternative and in vitro tests. Altern. Lab. Anim. 39(4), 317-337 (2011).
69. Eckstein P, Jackson MC, Millman N, Sobrero AJ. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J. Reprod. Fertil. 20(1), 85-93 (1969).
70. Zhong M, He B, Yang J et al. L-selectin and P-selectin are novel biomarkers of cervicovaginal inflammation for preclinical mucosal safety assessment of anti-HIV-1 microbicide. Antimicrob. Agents Chemother. 56(6), 3121-3132 (2012).
71. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. JAMA 296(7), 815-826 (2006).
72. Kumar V, Hassan MI, Tomar AK et al. Proteomic analysis of heparin-binding proteins from human seminal plasma: a step towards identification of molecular markers of male fertility. J. Biosci. 34(6), 899-908 (2009).
73. Keller MJ, Klotman ME, Herold BC. Rigorous pre-clinical evaluation of topical microbicides to prevent transmission of human immunodeficiency virus. J. Antimicrob. Chemother. 51(5), 1099-1102 (2003).
74. Sanchez MS, Grant RM, Porco TC, Getz WM. HIV drug-resistant strains as epidemiologic sentinels. Emerg. Infect. Dis. 12(2), 191-197 (2006).
75. Li L, Tan S, Lu H et al. Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection. J. Acquir. Immune Defic. Syndr. 56(5), 384-392 (2011).
76. Chaowanachan T, Krogstad E, Ball C, Woodrow KA. Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS ONE 8(4), e61416 (2013).
77. Cooper DA, Heera J, Goodrich J et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J. Infect. Dis. 201(6), 803-813 (2010).
78. Dezzutti CS, Shetler C, Mahalingam A et al. Safety and efficacy of tenofovir/IQP-0528 combination gels-a dual compartment microbicide for HIV-1 prevention. Antiviral Res. 96(2), 221-225 (2012).
79. Ferir G, Palmer KE, Schols D. Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C. Virology 417(2), 253-258 (2011).
80. Mccarthy TD, Karellas P, Henderson SA et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2(4), 312-318 (2005).
81. Fletcher PS, Wallace GS, Mesquita PM, Shattock RJ. Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. Retrovirology 3, 46 (2006).
82. Telwatte S, Moore K, Johnson A et al. Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1. Antiviral Res. 90(3), 195-199 (2011).
83. Basmaciogullari S, Babcock GJ, Van Ryk D, Wojtowicz W, Sodroski J. Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding. J. Virol. 76(21), 10791-10800 (2002).
84. Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49(11), 4721-4732 (2005).
85. Jenabian MA, Saidi H, Charpentier C et al. In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20). J. Antimicrob. Chemother. 64(6), 1192-1195 (2009).
86. Tremblay CL, Giguel F, Kollmann C et al. Anti-human immunodeficiency virus interactions of SCH-C (SCH 351125), a CCR5 antagonist, with other antiretroviral agents in vitro. Antimicrob. Agents Chemother. 46(5), 1336-1339 (2002).
87. Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking virus-cell and cell-cell fusion. J. Infect. Dis. 183(7), 1121-1125 (2001).
88. Balandya E, Sheth S, Sanders K, Wieland-Alter W, Lahey T. Semen protects CD4+ target cells from HIV infection but promotes the preferential transmission of R5 tropic HIV. J. Immunol. 185(12), 7596-7604 (2010).
89. Grivel JC, Shattock RJ, Margolis LB. Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J. Transl. Med. 9(Suppl. 1), S6 (2011).
90. Hoyle CE, Bowman CN. Thiol-ene click chemistry. Angew. Chem. Int. Ed. Engl. 49(9), 1540-1573 (2010).
91. Gali Y, Delezay O, Brouwers J et al. In vitro evaluation of viability, integrity, and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides. Antimicrob. Agents Chemother. 54(12), 5105-5114 (2010).
92. Pirrone V, Passic S, Wigdahl B, Krebs FC. Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1. Virol. J. 9, 33 (2012).
93. Mcgowan I. Microbicides: a new frontier in HIV prevention. Biologicals 34(4), 241-255 (2006).
94. Shattock RJ, Rosenberg Z. Microbicides: topical prevention against HIV. Cold Spring Harb. Perspect. Med. 2(2), a007385 (2012).
95. Neurath AR, Strick N, Li YY. Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides. BMC Infect. Dis. 6, 150 (2006).
96. Scordi-Bello IA, Mosoian A, He C et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob. Agents Chemother. 49(9), 3607-3615 (2005).
97. Munch J, Rucker E, Standker L et al. Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 131(6), 1059-1071 (2007).
98. Roan NR, Muller JA, Liu H et al. Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe 10(6), 541-550 (2011).
99. Barnabas RV, Celum C. Infectious co-factors in HIV-1 transmission herpes simplex virus type-2 and HIV-1: new insights and interventions. Curr. HIV Res. 10(3), 228-237 (2012).
100. Corey L. Synergistic copathogens-HIV-1 and HSV-2. N. Engl. J. Med. 356(8), 854-856 (2007).
101. Owen DH, Katz DF. A vaginal fluid simulant. Contraception 59(2), 91-95 (1999).